Non-Small Cell Lung Cancer Coverage from Every Angle

Silvia Novello, MD, PhD, on NSCLC Treatment Guided by Pharmacogenomics

Posted: Monday, February 8, 2021

Silvia Novello, MD, PhD, of the University of Turin, talks about how findings from the phase III ITACA trial on customizing treatment might influence clinical decision-making for patients with completely resected stage II to IIIA non–small cell lung cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.